Results for tag: "Malignant Pleural Mesothelioma Drug"

Malignant Pleural Mesothelioma (MPM) is a rare and aggressive form of cancer that affects the lining of the lungs and chest cavity. It is caused by exposure to asbestos and is most commonly diagnosed in individuals aged 50-70. Treatment for MPM typically involves a combination of chemotherapy, radiation therapy, and surgery. The MPM drug market is a rapidly growing segment of the oncology drug market. It is driven by the increasing prevalence of MPM, the development of new treatments, and the increasing demand for personalized therapies. The market is expected to witness significant growth in the coming years due to the increasing awareness of the disease and the availability of new treatments. Some of the key players in the MPM drug market include Bristol-Myers Squibb, Merck & Co., Pfizer, AstraZeneca, Novartis, and Eli Lilly. Show Less Read more